Research Article
Open Access
Novel RP-HPLC Analytical Method for Concurrent Quantification of Lamivudine, Tenofovir, and Efavirenz in Pharmaceutical Formulations
McAllister Muenster*, Kesik Brodacka
Department of Pharmacy, Uppsala University, Biomedical Centre P.O. Box 580, SE-751 23 Uppsala, Sweden
McAllister Muenster. Novel RP-HPLC Analytical Method for Concurrent Quantification of Lamivudine, Tenofovir, and Efavirenz in Pharmaceutical Formulations.Int.J. MediPharm Res. 2023,9(2),pp 20-24
Abstract
Background: A fast, reliable, and sensitive RP-HPLC method was developed for the simultaneous quantification of Lamivudine (3TC), Tenofovir (TFV), and Efavirenz (EFV) in pure form and their combined
pharmaceutical formulations.
Methods: The analysis was performed on an Inertsil ODS-3V column (250 × 4.6 mm, 5 μm) using an isocratic mobile phase composed of Acetonitrile and 1% Isopropyl Alcohol (IPA) in the ratio 85:15, flowing at 1 mL/min. Detection was carried out at 256 nm with a PDA detector.
Results: Retention times for 3TC, TFV, and EFV were observed at 2.4, 2.8, and 4.5 minutes, respectively (± 0.5 min). The method showed excellent linearity for all three drugs with correlation coefficients (R²) of 0.999. Recovery studies ranged between 98% and 102%, and precision (%RSD) values were below 2%. The method’s sensitivity was confirmed by determining the limits of detection (LOD) and quantification (LOQ), which were 0.06, 0.09, 0.17 μg/mL and 0.18, 0.27, 0.53 μg/mL for 3TC, TFV, and EFV, respectively.
Conclusion: This RP-HPLC method is rapid, robust, and highly reproducible, making it suitable for routine quality control and high-throughput analysis of these antiretroviral drugs in combined dosage forms. Its simplicity and accuracy ensure reliable application in pharmaceutical laboratories.
Keywords
Lamivudine; Tenofovir; Efavirenz; RP-HPLC; ICH guidelines; simultaneous estimation.
Full text content is not available right now.